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A B S T R A C T
Objectives: Osteogenesis Imperfecta (OI) is a heterogeneous condition mainly characterised by bone fragility;
intelligence is reported to be normal. However, a minority of children seen also show symptomology consistent
with an Autism Spectrum Disorder. A joint genetics and psychology research study was undertaken to identify
these patients using Gold Standard research tools: Autism Diagnostic Inventory Revised (ADI-R); Autism
Diagnostic Observation Schedule (ADOS) and undertake genetic analyses in them.
Method: A cohort of n=7 children with autistic traits and severe/complex OI were recruited to the study. The
study was set-up to explore whether there was a genetic link between bone fragility and autism in a sub-set of
patients with bone fragility identiﬁed with autism traits in our complex/severe OI clinic. This was not set-up as a
prevalence study but rather an exploration of genetics in association with ADI/ADOS conﬁrmed ASD and bone
fragility.
ADI& ADOS: Standardised tools were used to conﬁrm autism diagnosis. ADI and ADOS were completed by the
Clinical Psychologist; ADI comprises a 93 item semi-structured clinical review with a diagnostic algorithm di-
agnosing Autism; ADOS is a semi-structured assessment of socialisation, communication and play/imagination
which also provides a diagnostic algorithm.
Exome sequencing: In patients recruited, those that fulﬁlled research criteria for diagnosis of autism using above
tools were recruited to trio whole exome sequencing (WES).
Results: one patient had compound heterozygous variants in NBAS; one patient had a variant in NRX1; one
patient had a maternally inherited PLS3 variant; all the other patients in this cohort had pathogenic variants in
COL1A1/COL1A2.
Conclusions: Although, not set out as an objective, we were able to establish that identifying autism had im-
portant clinical and social beneﬁts for patients and their families in ensuring access to services, appropriate
schooling, increased understanding of behaviour and support.
Lay summary: It is important for clinicians looking after children with brittle bone disease, also referred to as
Osteogenesis Imperfecta (OI) to be aware of early features of developmental delay/autistic traits especially with
severe forms of OI as the emphasis is on their mobility and bone health. Ensuring appropriate assessment and
access to services early-on will enable these patients to achieve their potential. Further investigations of geno-
mics in bone fragility in relation to autism are required and dual diagnosis is essential for high quality clinical
and educational provision.
1. Introduction
Osteogenesis imperfecta is a heterogeneous group of disorders
characterised by bone fragility and fractures. Extra-skeletal features
such as hearing loss, dentinogenesis imperfecta and joint hypermobility
can also be variably present. The condition can be inherited in an au-
tosomal dominant or recessive pattern, or can be caused by a sporadic
mutation (de novo) in a proband (Balasubramanian M. Clinical and
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Molecular Heterogeneity of Osteogenesis Imperfecta, 2017). Osteo-
genesis imperfecta is the most common form of inherited bone fragility
disorder, with an estimated prevalence of 1 in 15,000 live births
(Folkestad et al., 2017). Incidence is approximately 1/15,0001/20,000
live births but this may be underestimated, as milder forms may not
have come to medical attention (Forlino and Marini, 2016).
The classiﬁcation of this disorder was traditionally based on severity
and inheritance. Previously, the four main types of osteogenesis im-
perfecta have been separated into the following distinct categories
(Sillence et al., 1979). A greater understanding of genetics has led to an
extension of the classiﬁcation of OI. Over 85% of mutations causing OI
are in the type 1 collagen genes (COL1A1 or COL1A2); the most
common being the replacement of a glycine amino acid in the (Gly  X 
Y)n repeating unit within the collagen triple helix. Apart from the type 1
collagen gene, many other genes are now conﬁrmed to be associated
with OI. Recurrent mutations in IFITM5 have been implicated in the
aetiology of Type V OI, which has an AD pattern of inheritance (Semler
et al., 2012; Cho et al., 2012).
OI Types VI-IX are inherited in an autosomal recessive (AR) pattern
(Gensure et al., 2005; Glorieux et al., 2002; Glorieux, 2005). Other
genes such as, CRTAP, P3H1, FKBP10, PPIB, SP7/Osterix (OSX), SER-
PINF1, SERPINH1, are associated with AR forms of OI (Alanay et al.,
2010; Baldridge et al., 2008; Christiansen et al., 2010; Lapunzina et al.,
2010; van Dijk et al., 2009). These forms are typically very severe if not
lethal. More recently several other recessive forms of OI- TMEM38B/
BMP1/CREB3L1/SPARC have been characterised (Shaheen et al., 2012;
Martínez-Glez et al., 2012; Symoens et al., 2013; Mendoza-Londono
et al., 2015) and X-linked forms of OI (PLS3/MBTPS2) (van Dijk et al.,
2009; Lindert et al., 2016) and heterozygous variants in WNT1/LRP5
(Laine et al., 2012; Hartikka et al., 2005) making OI a very genetically
heterogeneous condition and perhaps use of heritable bone fragility as a
more appropriate terminology to describe this group of conditions.
Rarely patients may present who do not ﬁt into the sub-categories of
this extended OI classiﬁcation. This may be because they have not yet
suﬀered a fracture, or because they present with other pathologies, such
as the syndromal features of facial dysmorphism, craniosynostosis or
contractures. They may have extreme short stature or developmental
delay. In these cases, it may be that the patient has an atypical diagnosis
of a type I collagenopathy (Balasubramanian et al., 2016). Some pa-
tients with bone fragility display autistic traits which are not in keeping
with their clinical diagnosis as children with OI are reported to have
normal intelligence; this would be classiﬁed as atypical bone fragility.
In the UK, the prevalence of autism is 1 in 100 (Baird et al., 2006).
Over the last 5 years, in our centre which has a large cohort of bone
fragility patients, it was our clinical observation that an unexpectedly
high number of children with bone fragility are also presenting with
clinical traits of ASD as characterised in DSM V (2013) (Autism
Spectrum Disorder 299.00 (F84.0) DSM-V, American Psychiatric
Association, 2013) (n=1015/102). We observed that the rate of af-
fected children appeared to be higher than expected from the latest ASD
population prevalence estimates of 1.9% (Baird et al., 2006) and
decided to study this in further detail. There is sparse evidence for this
association in the literature but in our clinical practice we have noted a
clear association, which seems more pronounced in children with re-
latively severe bone fragility.
The DSM V diagnostic criteria for ASD specify a child or adult must
show a) persistent deﬁcits in social communication and social interac-
tion, b) restricted and repetitive patterns of behaviour, c) symptoms
must be present in early developmental period, d) symptoms must
cause impairment in functioning and e) symptoms must not be better
explained by developmental delay. This study explored the association
between bone fragility and autism spectrum disorder in further detail
and set out to describe a novel phenotypic association.
2. Materials and methods
The research involved participation of children with OI from the
nationally-commissioned Severe and Complex OI group (total 102
children). Participants were recruited into a research project to study
the association of autism and OI and establish genotype: phenotype
correlations. Funding was obtained from the Newlife Charity and
ethical approval was obtained from the local regional ethics committee
(REC reference: 15/YH/0196) to undertake phenotyping and genetic
work-up in this group of patients.
From this group, we selected patients aged between 3 and 16 years
(total of 10 patients), who were reported to have diﬃculties with social
interaction by the multi-professional team. The Senior Clinical
Psychologist assessed these patients clinically for those who show signs
of ASD (n=10 children were noted to have atypical social skills, 7 of
these families were approached; all of them consented to participate in
the study). 3/10 patients: it was decided by the clinical team to not
approach children in whom atypical social skills were noted as it was
felt by the multidisciplinary team that the families would not be able to
deal with a diagnosis of autism in addition to the severe bone fragility.
Following informed consent from parents and their carers and where
applicable, assent from children, eligible children were recruited to the
study. This was not set out as a prevalence of autism in bone fragility
study (planned as a next step) but it is likely from our observation that
may be as high as 10% in our cohort.
Recruited children were screened for ASD traits using standardised
ASD clinical research tools. Sub-group of children who screened posi-
tive for ASD underwent a dysmorphology assessment and genetic
testing to identify common genotypes within this sub-group. We dis-
cussed results with families and onward referral to local child devel-
opment centres in those that fulﬁlled diagnostic criteria. This optimised
follow-up and support for families within ASD services locally along
with continued support within OI services.
2.1. ASD screening
Recruited children were screened by the Senior Clinical
Psychologist using the Autism Diagnostic Inventory  Revised (ADI-R)
and Autism Diagnostic Observation Schedule (ADOS).
2.1.1. Standardised psychological tests
2.1.1.1. ADI-R (Autism Diagnostic Inventory Revised) (Le Couteur et al.,
2008). The ADI-R is a clinical diagnostic instrument for assessing
autism in children and adults. It provides a diagnostic algorithm
consistent with DSM-IV and ICD-10 criteria for ASD. It consists of a
93-item semi-structured interview for parents/carers of people with
suspected ASD. The ADI-R scores are categorised into three domains of
communication and language, social interaction and restricted/
repetitive behaviours. A classiﬁcation of ASD is given when scores in
all three domains meet speciﬁed cut-oﬀs. The assessment can be
conducted from 4 years of age to adult.
2.1.1.2. ADOS (Autism Diagnostic Observation Schedule) (Lord et al.,
1997). The ADOS is a semi-structured assessment and observation of
socialisation, communication and restricted/repetitive behaviours. The
ADOS is completed by the clinician directly with the child and includes
various activities designed to elicit behaviours that are coded to inform
an ASD diagnosis. Sub-sections are coded using an algorithm; children
score in the categories of Non-spectrum, Autism or Autism-Spectrum.
The assessment can be conducted from 12-months of age to adult.
From this group, children identiﬁed as having ASD using ADI-R and
ADOS were included for genetic assessment.
2.2. Genetic assessment
From the children recruited, those that screened positive for a
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diagnosis of ASD/Autism using the ADI-R and ADOS screening tools,
were invited for a genetic assessment by the Consultant Clinical
Geneticist. These patients underwent assessments including detailed
family pedigree and dysmorphology examination to ascertain if there
are other genetic reasons for the ASD (i.e. dual diagnoses). Following
appropriate consent, clinical photographs were taken and blood sam-
ples obtained for genetic analysis. The Clinical Geneticist assessed these
patients and performed a comprehensive dysmorphology examination
to ascertain whether ASD is part of a syndromal diagnosis or whether
there are other contributory factors within the family and/or medical
history.
2.3. Genetic analyses
Samples were analysed from those that screened positive on ASD
assessments for 60 K microarrays which is a detailed analysis of chro-
mosomes and next-generation sequencing of genes implicated in ASD/
Autism (autism/developmental delay gene panel). Common variants
were identiﬁed from within this cohort of patients.
3. Clinical report
In total seven patients were recruited to the study and underwent
autism and genetics assessments. We did not approach all the families
identiﬁed by the clinical team where this was not considered to be
appropriate at that point in time (n=3). Below are detailed summaries
of patients recruited and assessment outcomes.
3.1. Patient 1
Patient 1 was an 11-year old boy, the second child of non-con-
sanguineous parents. There was no family history of bone fragility or
autism. The pregnancy was normal, and the patient was delivered by
caesarean section post term after failure of labour progression. He was
treated in the Special Care Baby Unit for two days after delivery due to
pyrexia. He was born with left-sided calcaneus talipes equinovarus and
right-sided developmental dysplasia of the hip. His undescended testes
were operated on successfully.
Patient 1 is developmentally delayed. He walked at 2.5 years of age
and had delayed onset of speech. He had diﬃculties with ﬁne motor
skills and attended a school for children with special needs. This patient
had a clinical diagnosis of ASD made at 5-years of age. His parents also
reported ritualistic behaviours, resulting in a referral to Child and
Adolescent Mental Health Services for an assessment of possible ob-
sessive compulsive disorder.
He was noted to have previously suﬀered ﬁnger fractures and a
decrease in vertebral height. A DXA scan to measure his bone mineral
density (BMD) undertaken before commencement of bisphosphonate
treatment demonstrated a reduced BMD with Z-scores of −3.4 at the
lumbar vertebrae and a total body score of−2.5 when adjusted for age
and gender. A bone biopsy had demonstrated low turnover trabecular
osteopenia consistent with osteoporosis.
Also of note, he had diagnoses of asthma and idiopathic generalised
epilepsy. He suﬀered from intermittent neutropenia thought to be the
result of sodium valproate therapy. He received 3-monthly pamidronate
infusions, remained on melatonin daily and had been prescribed mid-
azolam, to be given in the event of a prolonged seizure.
On examination, he had bilateral low-set ears, blue sclerae and
glasses due to hyperopia.
Trio whole exome sequencing (WES) in him identiﬁed a de novo
missense variant in NRXN1 which is known to be associated with
neurodevelopmental disorders/autism and being further investigated as
it is known to interact with COL1A1.
3.2. Patient 2
Patient 2 was an 11-year old boy, the second child to healthy, non-
consanguineous parents. There is no family history of bone fragility and
autism. He was born in the breech position spontaneously at 32-weeks
gestation after the pregnancy was complicated by placental abruption,
causing severe abdominal pain and heavy bleeding. At birth, he
weighed 1.76 kg (9th centile); he required continuous positive airway
pressure for 24 h and phototherapy to treat his neonatal jaundice. He
was fed via a nasogastric tube for the ﬁrst week of life.
He failed to thrive throughout childhood with height and weight
below the 0.4th centile and head circumference 0.4th-2nd centile, with
insuﬃcient weight gain resulting in the insertion of a percutaneous
gastrostomy for nutritional support. He suﬀered frequent infections
including bronchiolitis, pneumonia and urinary tract infections. A
micturating cystourethrogram identiﬁed bilateral vesicoureteric reﬂux.
He had consistent hypogammaglobulinaemia and lymphopenia
throughout childhood with poor vaccine responses. This patient re-
ceived 3-weekly immunoglobulin replacement therapy. Also of note, he
had bilateral optic atrophy and consistently abnormal liver function
tests.
Patient 2 had severe intellectual disability. He had delayed speech
and suﬀers from gross and ﬁne motor delay: he ﬁrst walked at
19months. He demonstrated signiﬁcant echolalia and restricted inter-
ests; the patient had received a clinical diagnosis of ASD at 6-years of
age.
He had suﬀered several fractures of the vertebrae, metatarsals and
tibias. A bone biopsy at 7-years of age demonstrated a high rate of bone
turnover and osteopenia, with marked subperiosteal bone resorption.
DXA scans showed reduced bone mineral density, however it was dif-
ﬁcult to determine the degree of reduction due to his small size. He
received 3-monthly pamidronate infusions.
The patient had undergone numerous investigations throughout his
life to provide an explanation for his clinical features. Trio WES iden-
tiﬁed that patient 2 is compound heterozygous for c.3010C>T and
c.5741G>A pathogenic mutations in the NBAS gene
(Balasubramanian et al., 2017). He had been diagnosed with SOPH
syndrome (Short Stature, Optic Atrophy, Pelger-Huet anomaly), which
largely explains the patient's clinical picture. On examination, he had
short stature and high pitched voice. Facial dysmorphism included a
prominent forehead, low set ears, hypertelorism, proptosis, progeric
appearance to his skin and up-slanted palpebral ﬁssures.
3.3. Patient 3
Patient 3 was a 4-year old boy, the third child of healthy, non-
consanguineous parents. There was no family history of bone fragility
or autism. Bowing of the lower limbs observed on the anomaly scan
raised antenatal suspicion of a campomelic dysplasia. The patient was
born by normal vaginal delivery at term. He weighed 3.74 kg (50th
centile) with a head circumference of 34 cm (25th centile). He suﬀered
mild respiratory distress at birth but did not require ventilatory support.
A skeletal survey performed after birth demonstrated a normal
thoracic cage volume, bowing of the long bones with abnormal meta-
physes and a fractured ulna. The patient suﬀered fractures to his left
humerus and right forearm. He was subsequently diagnosed with severe
osteogenesis imperfecta.
By 4-years of age, he had suﬀered multiple fractures of his ulnas and
humeri, a femoral fracture and multiple vertebral wedge fractures. He
has undergone bilateral osteotomies and rodding of his femurs and ti-
bias at 2 and 3 years of age, respectively. He received 3-monthly pa-
midronate infusions.
This patient was developmentally delayed, sat independently from
2 years and walked with aids from 2.5 years of age. He had delayed
speech and required intervention from speech and language therapists
at age 21months. He has demonstrated rocking behaviour from
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2.5 years of age but did not have a clinical diagnosis of ASD before
recruitment to the study.
On genetic assessment, he was noted to have a triangular face, blue
sclerae, high-pitched voice in keeping with a diagnosis of Classical OI.
He went on to have testing for COL1A1/A2 and was found to have a
pathogenic c.902G>A variant in COL1A2. This pathogenic mutation is
predicted to replace glycine at position 301 with a glutamic acid.
Glycine substitutions are well-recognised as a cause of OI. This con-
ﬁrmed his clinical diagnosis of OI.
3.4. Patient 4
Patient 4 was a 14-year old male, the only child born to non-con-
sanguineous parents. His younger half-brother (through same mother)
had learning diﬃculties but there was no other family history of autism.
The pregnancy was normal with delivery by caesarean section at
39 weeks due to a breech presentation. He had a birth weight of 3.54 kg
(65th centile). He needed oxygen shortly after delivery but was not
admitted to the Special Care Baby Unit. He had global developmental
delay: no head control was evident at 4months; sitting was achieved at
2 years of age; the patient walked at 4.5 years and currently uses a
wheelchair. He spoke his ﬁrst words aged 7 years. He was doubly in-
continent and has learning diﬃculties; he attended a school for children
with special needs. He was diagnosed with ASD at 5-years of age, before
recruitment to the study after demonstrating little eye contact and
having restricted interests. He had previously engaged in self-harm
behaviour such as head banging and biting.
Patient 4 had suﬀered from a fractured forearm and vertebral wedge
fractures. He had been given a diagnosis of probable primary osteo-
porosis, suﬀering discomfort in his back and lower limbs. DXA scanning
undertaken before commencing 3-monthly pamidronate infusions de-
monstrated a reduced BMD when adjusted for age and gender of −2.6
at lumbar vertebrae 24 and a total body measurement of−2.7. He had
joint hypermobility and brittle nails.
This patient was diagnosed with bilateral femoral proximal ante-
version, which was operated on with a derotation osteotomy. He de-
monstrated ligamentous laxity and suﬀered a leg length discrepancy.
The patient had a small scrotum and incomplete descended testes. He
also had left sided choroidal coloboma and myopia.
On examination, he was not dysmorphic. So far WES in him has not
identiﬁed any variants of signiﬁcance and further genetic analysis is
ongoing.
3.5. Patient 5
Patient 5 was a 13-year old male, the ﬁrst child to healthy, non-
consanguineous parents. There was a family history of osteoporosis in
his maternal grandfather but no family history of autism. The preg-
nancy was not planned and was not detected until approximately
25 weeks. No scans were performed. He was born at term and was
immediately well after birth.
His initial development was normal, with gross motor milestones
being achieved as expected: he sat up aged 6months and walked at age
8months. His speech was delayed; he started speaking at 5 years of age
after receiving speech therapy. He was diagnosed with ASD at 3-years
of age after concerns were raised at his toddler group. The patient at-
tended a school for children with special needs.
He had suﬀered three fractures: two of his forearm and one of his
wrists. Additionally, he had suﬀered from multiple crush fractures of
his thoracic and lumbar vertebrae. The small joints of the ﬁngers were
hypermobile, but there was little evidence of hypermobility elsewhere.
DXA scans undertaken before commencing bisphosphonate treatment
demonstrated reduced BMD, with Z-scores of −2.7 at the lumbar ver-
tebrae and− 2.6 total body measurement when adjusted for age and
gender. He had a diagnosis of idiopathic osteoporosis with a bone
biopsy at 12-years of age demonstrating severe low turnover cortical
and trabecular osteopenia. The patient received 3-monthly infusions of
pamidronate.
On examination, this patient was not dysmorphic. WES identiﬁed a
maternally inherited PLS3 pathogenic variant which explained his bone
fragility.
3.6. Patient 6
Patient 6 was an eight year old boy, the second child of healthy,
non-consanguineous parents. There was no family history of bone fra-
gility or autism. Shortened long bones were identiﬁed on the 16-week
scan and the child was delivered by caesarean section at 37-weeks. At
birth, he needed ventilation with a bag and mask. He was born with
fractures of all the long bones and multiple ribs: he was diagnosed with
severe OI antenatally. The patient was treated in the special care baby
unit for three months; he was fed via a nasogastric tube and suﬀered
from gastroesophageal reﬂux.
He developed a right sided inguinal hernia shortly after birth which
was surgically corrected at one month of age. He also suﬀered from
fusion between the base of his skull and top of his spinal column.
Throughout his life, he had suﬀered multiple long bone fractures, in-
cluding several femoral fractures and fractures of his radii. He had
undergone several surgical procedures, with bilateral femoral and tibial
rodding procedures undertaken at 4 and 5 years of age, respectively. His
bone fragility was managed with 3-monthly infusions of pamidronate.
He was developmentally delayed: he started talking between two
and a half and three years of age and started to commando crawl at
3 years of age. He had never walked. The patient attended a mainstream
school after starting a year later than his peers. He did not have a
previous diagnosis of ASD.
On examination, he had short stature, blue sclerae, triangular face
and dentinogenesis imperfecta. There were marked deformities of his
long bones, resulting in a pes cavus appearance. Genetic testing showed
that he carried a de novo pathogenic variant in COL1A1 c.2282G>A in
exon 33/34 conﬁrming his clinical diagnosis of OI.
3.7. Patient 7
Patient 7 was a 6-year old boy, second child of healthy, non-con-
sanguineous parents with no signiﬁcant family history. His sister was
said to have a seizure disorder of unknown aetiology but there was no
family history of autism. Antenatally, there were concerns with short
long bones and bowed femur and he was born at term with a normal
birth weight. He was noted to have multiple fractures and commenced
on treatment with pamidronate with a good response. He was noted by
the therapy team to have autistic traits and recruited to the study. He
fulﬁlled the criteria for a diagnosis of autism. On examination, he had a
triangular face, blueish sclerae, high-pitched voice, dentinogenesis
imperfecta, signiﬁcant limb deformities and scoliosis. Genetics analyses
revealed normal microarrays and a pathogenic variant was identiﬁed in
COL1A2 conﬁrming his clinical diagnosis of OI. c.2533G>A mutation
in exon 37 of COL1A2 gene, this pathogenic mutation is predicted to
replace glycine at position 845 with an arginine and has previously
been reported in individuals with OI conﬁrming his diagnosis.
4. Molecular analysis
4.1. Patient 1
Unclassiﬁed de novo missense variant in NRXN1 being further in-
vestigated.
4.2. Patient 2
Compound heterozygous for NBAS variants; maternally inherited
c.3010C>T variant and paternally inherited c.5741G>A variant
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(Balasubramanian et al., 2017).
4.3. Patient 3
De novo pathogenic c.902G>A variant in COL1A2.
4.4. Patient 4
No causative variant identiﬁed so far on exome sequencing.
4.5. Patient 5
Hemizygous for a maternally inherited, c.1295T>A pathogenic
mutation in exon 12 of PLS3.
4.6. Patient 6
De novo pathogenic variant in COL1A1 c.2282G>A in exon 33/34
conﬁrming his clinical diagnosis.
4.7. Patient 7
De novo pathogenic c.2533G>A mutation in exon 37 variant was
identiﬁed in COL1A2 conﬁrming his clinical diagnosis. Table 1 provides
a detailed overview of recruited patients and corrsponding genotype.
5. Discussion
Children with OI/heritable bone fragility are said to have normal
intellectual development and the emphasis is usually on the motor
delay (Balasubramanian et al., 2017). Autism spectrum disorder (ASD)
is not a proven association and is often overlooked in this group. This
results in delayed diagnosis and input, thereby leading to reduced im-
pact of early intervention within this group.
Diagnosis of ASD takes considerable time and may not occur in the
early years of a child's life (Zwaigenbaum et al., 2013). Zwaigenbaum
et al., 2013 in a recent review concluded that early diagnosis of ASD
enhances the impact of interventions and reduces parental burden.
Families experience signiﬁcant stress and uncertainty during this period
and interventions designed to reduce symptoms and improve func-
tioning are delayed due to late interventions. This delay is further
compounded in children with bone fragility due to their disability po-
tentially masking ASD symptoms. We have observed an increased in-
cidence of ASD within our OI cohort (n=10 out of 102) based on
general population estimates of 1 in 100 children (Baird et al., 2006).
ASD and heritable bone fragility are not known to be associated
disorders. There is emerging evidence to suggest that patients with
autism spectrum disorders (ASD) are at an increased risk for fractures
and peri-pubertal boys with ASD have lower BMD than age-matched
controls (Ekhlaspour et al., 2016). A study performed by Neumeyer
et al., 2013 evidenced a lower bone mineral (BMD) density in boys with
ASD than controls. It has been found that children with ASD are at an
increased predisposition to a fracture of any kind than those without
the disorder (Furlano et al., 2014) and people below the age of 50 with
ASD are at increased risk of suﬀering a hip fracture than controls
(Neumeyer et al., 2015).
It has so far been thought any association between bone fragility
and ASD is environmental in origin, due to a diet insuﬃcient in vitamin
D or lack of physical activity (Neumeyer et al., 2013) and there is no
literary evidence of a syndromal condition consisting of genetic bone
fragility and ASD. More recently, studies by Neumeyer et al., 2017a
and, 2017b have very well demonstrated that bone accrual and bone
microarchitecture is impaired in ASD with reduction in bone strength
and resultant low BMD. This may yet be attributable to low levels of
physical activity and calcium intake in children with ASD but it is also
plausible that there may be as yet un-identiﬁed genetic modiﬁers that
play a role in this predisposition. The study described here comes from
the opposite angle: identifying patients with severe bone fragility and
pointing out the increased incidence of ASD in this cohort which would
be worth investigating further in a larger cohort of patients.
This study undertook detailed clinical and molecular phenotyping in
a cohort of children presenting with autistic traits and bone fragility; to
determine if this is a novel phenotype and whether they share a
common genetic aetiology; and add clinical deﬁnition to the association
of ASD and OI. A similar example would be the identiﬁcation of an
association between OI and a profound neurological phenotype caused
due to mutations in WNT1 (Fahiminiya et al., 2013; Faqeih et al.,
2013). This has led to further studies demonstrating the eﬀect of WNT-
ß Catenin signaling pathway on cellular diﬀerentiation in both the
skeleton and the central nervous system (Palomo et al., 2014; Tang,
2014). Identiﬁcation of similar ﬁndings in this condition would be only
be possible by a thorough dysmorphic assessment and genetic analyses
in order to establish common phenotypic and genotypic characteristics.
In our cohort, we identiﬁed diverse genotypes as opposed to a single
genetic aetiology which reﬂects the genetic heterogeneity of both ASD
and bone fragility. Type 1 collagen variants were the most common
which reﬂects the most common cause of OI; NRXN1 is known to be
associated with ASD and it would be interesting to explore how this
links with the bone fragility. NBAS is known to cause SOPH syndrome
and PLS3 are known to be associated with heritable bone fragility but
autism is not a known association with these genes. It is likely that
similar to high risk candidate genes in ASD (https://www.sfari.org/
resource/sfari-gene/), there is going to be diverse genotypes in this
group. Further studies to explore this association and undertake deep
sequencing in this cohort may well identify other candidate genes and
interacting biological pathways that may be relevant.
Although as detailed in the Results section above, we have not
been able to identify a common molecular aetiology for patients pre-
senting with bone fragility and ASD, we have been able to determine
that patients with bone fragility, especially those at the severe end of
Table 1
Description of clinical phenotype and genotype in autism and bone fragility cohort.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age 11-years 11-years 4-years 14-years 13-years 8-years 6-years
Family History NA NA NA ID in half-
brother
Osteoporosis in
maternal
grandfather
NA Seizure disorder in
sister
Fractures ++ ++ ++ ++ + ++ +++
Pamidronate Yes Yes Yes Yes Yes Yes Yes
ID Moderate-severe Moderate-Severe Moderate Moderate-severe Mild Severe Severe
ASD Yes Yes Yes Yes Yes Yes Yes
Molecular
analysis
NRXN1 c.1273T>A
de novo missense
variant
NBAS c.3010C>T
and c.5741G>A
variants
COL1A2
c.902G>A de novo
variant
No causal
variants so far
on WES
PLS3 c.1295T>A
mat variant
COL1A1
c.2282G>A de novo
variant
COL1A2
c.2533G>A de novo
variant
ID: Intellectual disability; ASD: Autism spectrum disorder; NA: Not applicable.
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the spectrum/presentation with additional clinical features, seem to
have a higher incidence of ASD. Being able to undertake detailed autism
assessments in this group has allowed earlier diagnosis in some of the
younger patients within this group. The numbers studied here are small
and there is a planned national study across more centres which may
help deﬁne this association further.
As expected from the literature, the majority of patients recruited to
the study have variants in COL1A1/A2, the commonest genes asso-
ciated with OI. It would be interesting to ascertain through a national
study with larger patients' number whether there are additional risk
factors early on in life that contribute to an increased incidence of
autistic traits in patients presenting with severe bone fragility and type
1 collagen variants.
6. Summary
By exploring the genetic causality of autism in bone fragility, we are
essentially identifying a genetic link between autism and childhood
bone fragility. Osteogenesis Imperfecta which is the commonest in-
herited form of bone fragility does not usually present with intellectual
disability and/or autism and hence, proving this association will be
crucial in informing early diagnoses and prognostic information for
families with this rare bone disease. From the study undertaken in
seven families so far, we have been able to show that early diagnosis
impacts educational support and allocation of additional resources for
children who already have very complex medical needs.
Therefore, it is important for clinicians treating children with OI to
be aware of this potential association, have a high index of suspicion
when children display autistic traits, and to refer for an autism as-
sessment and formal diagnosis so as to ensure adequate support is
provided early on in a child's development. It requires a shift in focus of
children with bone fragility care to not just be targeted at their fracture
management and motor development but also focused on their in-
tellectual development. With better treatments for bone fragility be-
coming available, it is important that these children are adequately
supported so they can reach their full potential not only in terms of
their physical health but also their mental wellbeing. It is also im-
portant that further studies are undertaken to explore this association
and draw ﬁrmer conclusion on this associated phenotypes.
Acknowledgements
We would like to thank the families for consenting to publication of
their details; Newlife Foundation for Disabled Children Grant
Reference: SG/14-15/05 and The Sheﬃeld Children's Hopsital Chairty
(TCHC) (for Patient 2) Grant Reference: CA15001 for their generous
funding to this study.
Conﬂicts of interests
The authors declare that they have no conﬂict of interest in relation
to this manuscript.
Statement
This study has been approved by the South Yorkshire Research
Ethics Committee (REC reference: 15/YH/0196) and appropriate in-
stitutional boards and the research has been performed in accordance
with the 1964 Helsinki Declaration. All authors contributed to this
manuscript.
References
Alanay, Y., Avaygan, H., Camacho, N., Utine, G.E., Boduroglu, K., Aktas, D., Alikasifoglu,
M., Tuncbilek, E., Orhan, D., Bakar, F.T., Zabel, B., Superti-Furga, A., Bruckner-
Tuderman, L., Curry, C.J., Pyott, S., Byers, P.H., Eyre, D.R., Baldridge, D., Lee, B.,
Merrill, A.E., Davis, E.C., Cohn, D.H., Akarsu, N., Krakow, D., 2010. Mutations in the
gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis im-
perfecta. Am. J. Hum. Genet. 86 (4), 551559.
Autism Spectrum Disorder 299.00 (F84.0) DSM-V, American Psychiatric Association,
2013.
Baird, G., Simonoﬀ, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., Charman, T.,
2006. Prevalence of disorders of the autism spectrum in a population cohort of
children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368
(9531), 210215.
Balasubramanian M. Clinical and Molecular Heterogeneity of Osteogenesis Imperfecta,
2017. Colloquium Series on Genomic and Molecular Medicine. vol. 8 Morgan &
Claypool Life Sciences Publishers, San Rafael, CA/United States.
Balasubramanian, M., Cartwright, A., Smith, K., Arundel, P., Bishop, N.J., 2016. Copy
number variants in association with type 1 collagenopathy: atypical osteogenesis
imperfecta. Am. J. Med. Genet. A 170A (2), 476481.
Balasubramanian, M., Hurst, J., Brown, S., Bishop, N.J., Arundel, P., DeVile, C., Pollitt,
R.C., Crooks, L., Longman, D., Caceres, J.F., Shackley, F., Connolly, S., Payne, J.H.,
Oﬃah, A.C., Hughes, D., Study, D.D.D., Parker, M.J., Hide, W., Skerry, T.M., 2017
Jan. Compound heterozygous variants in NBAS as a cause of atypical osteogenesis
imperfecta. Bone 94, 6574.
Baldridge, D., Schwarze, U., Morello, R., Lennington, J., Bertin, T.K., Pace, J.M., Pepin,
M.G., Weis, M., Eyre, D.R., Walsh, J., Lambert, D., Green, A., Robinson, H.,
Michelson, M., Houge, G., Lindman, C., Martin, J., Ward, J., Lemyre, E., Mitchell, J.J.,
Krakow, D., Rimoin, D.L., Cohn, D.H., Byers, P.H., Lee, B., 2008. CRTAP and LEPRE1
mutations in recessive osteogenesis imperfecta. Hum. Mutat. 29 (12), 14351442.
Cho, T.J., Lee, K.E., Lee, S.K., Song, S.J., Kim, K.J., Jeon, D., Lee, G., Kim, H.N., Lee, H.R.,
Eom, H.H., Lee, Z.H., Kim, O.H., Park, W.Y., Park, S.S., Ikegawa, S., Yoo, W.J., Choi,
I.H., Kim, J.W., et al., 2012. A single recurrent mutation in the 5-UTR of IFITM5
causes osteogenesis imperfecta type V. Am. J. Hum. Genet. 91 (2), 343348.
Christiansen, H.E., Schwarze, U., Pyott, S.M., AlSwaid, A., Al Balwi, M., Alrasheed, S.,
Pepin, M.G., Weis, M.A., Eyre, D.R., Byers, P.H., 2010. Homozygosity for a missense
mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results
in severe recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86 (3), 389398.
van Dijk, F.S., Nesbitt, I.M., Zwikstra, E.H., Nikkels, P.G., Piersma, S.R., Fratantoni, S.A.,
Jimenez, C.R., Huizer, M., Morsman, A.C., Cobben, J.M., van Roij, M.H., Elting,
M.W., Verbeke, J.I., Wijnaendts, L.C., Shaw, N.J., Högler, W., McKeown, C.,
Sistermans, E.A., Dalton, A., Meijers-Heijboer, H., Pals, G., 2009. PPIB mutations
cause severe osteogenesis imperfecta. Am. J. Hum. Genet. 85 (4), 521527.
Ekhlaspour, L., Baskaran, C., Campoverde, K.J., Sokoloﬀ, N.C., Neumeyer, A.M., Misra,
M., 2016. Bone density in adolescents and young adults with autism spectrum dis-
orders. J. Autism Dev. Disord. 46 (11), 33873391.
Fahiminiya, S., Majewski, J., Mort, J., Moﬀatt, P., Glorieux, F.H., Rauch, F., 2013.
Mutations in WNT1 are a cause of osteogenesis imperfecta. J. Med. Genet. 50 (5),
345348.
Faqeih, E., Shaheen, R., Alkuraya, F.S., 2013. WNT1 mutation with recessive osteogenesis
imperfecta and profound neurological phenotype. J. Med. Genet. 50 (7), 491492.
Folkestad, L., Hald, J.D., Ersbøll, A.K., Gram, J., Hermann, A.P., Langdahl, B.,
Abrahamsen, B., Brixen, K., 2017. Fracture rates and fracture sites in patients with
osteogenesis imperfecta: a nationwide register-based cohort study. J. Bone Miner.
Res. 32 (1), 125134.
Forlino, A., Marini, J.C., 2016 Apr 16. Osteogenesis imperfecta. Lancet 387 (10028),
16571671.
Furlano, R.I., Bloechliger, M., Jick, H., Meier, C.R., 2014. Bone fractures in children with
autistic spectrum disorder. J. Dev. Behav. Pediatr. 35, 353359.
Gensure, R.C., Makitie, O., Barclay, C., Chan, T.F., Depalma, S.R., Bastepe, M., Abuzahra,
H., Couper, R., Mundlos, S., Sillence, D., Ala-Kokko, L., Seidman, J.G., Cole, W.G.,
Juppner, H., 2005. A novel COL1A1 mutation in infantile cortical hyperostosis
(Caﬀey disease) expands the spectrum of collagen-related disorders. J. Clin. Invest.
115, 12501257.
Glorieux, F.H., 2005. Caﬀey disease: an unlikely collagenopathy. J. Clin. Invest. 115 (5),
11421144.
Glorieux, F.H., Ward, L.M., Rauch, F., Lalic, L., Roughley, P.J., Travers, R., 2002.
Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization
defect. J. Bone Miner. Res. 17 (1), 3038.
Hartikka, H., Mäkitie, O., Männikkö, M., Doria, A.S., Daneman, A., Cole, W.G., Ala-Kokko,
L., Sochett, E.B., 2005. Heterozygous mutations in the LDL receptor-related protein 5
(LRP5) gene are associated with primary osteoporosis in children. J. Bone Miner. Res.
20 (5), 783789.
Laine, C.M., Koltin, D., Susic, M., Varley, T.L., Daneman, A., Moineddin, R., Cole, W.G.,
Mäkitie, O., Sochett, E., 2012. Primary osteoporosis without features of OI in children
and adolescents: clinical and genetic characteristics. Am. J. Med. Genet. A 158A (6),
12521261.
Lapunzina, P., Aglan, M., Temtamy, S., Caparrós-Martín, J.A., Valencia, M., Letón, R.,
Martínez-Glez, V., Elhossini, R., Amr, K., Vilaboa, N., Ruiz-Perez, V.L., 2010.
Identiﬁcation of a frameshift mutation in Osterix in a patient with recessive osteo-
genesis imperfecta. Am. J. Hum. Genet. 87 (1), 110114.
Le Couteur, A., Haden, G., Hammal, D., McConachie, H., 2008 Feb. Diagnosing autism
spectrum disorders in pre-school children using two standardised assessment in-
struments: the ADI-R and the ADOS. J. Autism Dev. Disord. 38 (2), 362372.
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E.,
Leboyer, M., Minshew, N., 1997 Oct. Diagnosing autism: analyses of data from the
Autism Diagnostic Interview. J. Autism Dev. Disord. 27 (5), 501517.
Lindert, U., Cabral, W.A., Ausavarat, S., Tongkobpetch, S., Ludin, K., Barnes, A.M.,
Yeetong, P., Weis, M., Krabichler, B., Srichomthong, C., Makareeva, E.N., Janecke,
A.R., Leikin, S., Röthlisberger, B., Rohrbach, M., Kennerknecht, I., Eyre, D.R.,
Suphapeetiporn, K., Giunta, C., Marini, J.C., Shotelersuk, V., 2016 Jul 6. MBTPS2
M. Balasubramanian et al. %RQH5HSRUWV²

mutations cause defective regulated intramembrane proteolysis in X-linked osteo-
genesis imperfecta. Nat. Commun. 7, 11920.
Martínez-Glez, V., Valencia, M., Caparrós-Martín, J.A., Aglan, M., Temtamy, S., Tenorio,
J., Pulido, V., Lindert, U., Rohrbach, M., Eyre, D., Giunta, C., Lapunzina, P., Ruiz-
Perez, V.L., 2012. Identiﬁcation of a mutation causing deﬁcient BMP1/mTLD pro-
teolytic activity in autosomal recessive osteogenesis imperfecta. Hum. Mutat. 33 (2),
343350.
Mendoza-Londono, R., Fahiminiya, S., Majewski, J., Care4Rare Canada Consortium,
Tétreault, M., Nadaf, J., Kannu, P., Sochett, E., Howard, A., Stimec, J., Dupuis, L.,
Roschger, P., Klaushofer, K., Palomo, T., Ouellet, J., Al-Jallad, H., Mort, J.S., Moﬀatt,
P., Boudko, S., Bächinger, H.P., Rauch, F., 2015 Jun 4. Recessive osteogenesis im-
perfecta caused by missense mutations in SPARC. Am. J. Hum. Genet. 96 (6),
979985.
Neumeyer, A.M., Gates, A., Ferrone, C., Lee, H., Misra, M., 2013. Bone density in peri-
pubertal boys with autism spectrum disorders. J. Autism Dev. Disord. 43, 16231629.
Neumeyer, A.M., O'Rourke, J.A., Massa, A., Lee, H., Lawson, E.A., McDougle, C.J., Misra,
M., 2015. Brief report: bone fractures in children and adults with autism spectrum
disorders. J. Autism Dev. Disord. 45, 881887.
Neumeyer, A.M., Cano Sokoloﬀ, N., Mc Donnell, E., Macklin, E.A., CJ, McDougle, Misra,
M., 2017 Feba. Bone accrual in males with autism spectrum disorder. J. Pediatr. 181,
195-201.e6.
Neumeyer, A.M., Cano Sokoloﬀ, N., McDonnell, E., Macklin, E.A., McDougle, C.J., Misra,
M., 2017 Aprb. Bone microarchitecture in adolescent boys with autism spectrum
disorder. Bone 97, 139146.
Palomo, T., Al-Jallad, H., Moﬀatt, P., Glorieux, F.H., Lentle, B., Roschger, P., Klaushofer,
K., Rauch, F., 2014 Jul 8. Skeletal characteristics associated with homozygous and
heterozygous WNT1 mutations. Bone 67C, 6370.
Semler, O., Garbes, L., Keupp, K., Swan, D., Zimmermann, K., Becker, J., Iden, S., Wirth,
B., Eysel, P., Koerber, F., Schoenau, E., Bohlander, S.K., Wollnik, B., Netzer, C., et al.,
2012. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes
autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am. J.
Hum. Genet. 91 (2), 349357.
Shaheen, R., Alazami, A.M., Alshammari, M.J., Faqeih, E., Alhashmi, N., Mousa, N.,
Alsinani, A., Ansari, S., Alzahrani, F., Al-Owain, M., Alzayed, Z.S., Alkuraya, F.S.,
2012. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel
locus deﬁned by TMEM38B mutation. J. Med. Genet. 49 (10), 630635.
Sillence, D.O., Senn, A., Danks, D.M., 1979 Apr. Genetic heterogeneity in osteogenesis
imperfecta. J. Med. Genet. 16 (2), 101116.
Symoens, S., Malfait, F., D'Hondt, S., Callewaert, B., Dheedene, A., Steyaert, W.,
Bachinger, H.P., De Paepe, A., Kayserili, H., Coucke, P.J., 2013. Deﬁciency for the ER-
stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans.
Orphanet J. Rare Dis. 8, 154.
Tang, S.J., 2014. Editorial: W(e)NT to the brain: WNT signaling in neurological disorders.
CNS Neurol. Disord. Drug Targets 13 (5), 736.
Zwaigenbaum, L., Bryson, S., Garon, N., 2013. Early identiﬁcation of autism spectrum
disorders. Behav. Brain Res. 251, 133146.
M. Balasubramanian et al. %RQH5HSRUWV²

